BIOMAT Database Logo BIOMAT Database Logo

In Vitro and In Vivo Trypanosomicidal Action of Novel Arylimidamides against Trypanosoma cruzi. 2016

F H Guedes-da-Silva, and D G J Batista, and M B Meuser, and K C Demarque, and T O Fulco, and J S Araújo, and P B Da Silva, and C F Da Silva, and D A Patrick, and S M Bakunova, and S A Bakunov, and R R Tidwell, and G M Oliveira, and C Britto, and O C Moreira, and M N C Soeiro
Laboratório de Biologia Celular, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, RJ, Brazil.

Arylimidamides (AIAs) have been shown to have considerable biological activity against intracellular pathogens, includingTrypanosoma cruzi, which causes Chagas disease. In the present study, the activities of 12 novel bis-AIAs and 2 mono-AIAs against different strains ofT. cruziin vitroandin vivowere analyzed. The most active wasm-terphenyl bis-AIA (35DAP073), which had a 50% effective concentration (EC50) of 0.5 μM for trypomastigotes (Y strain), which made it 26-fold more effective than benznidazole (Bz; 13 μM). It was also active against the Colombiana strain (EC50= 3.8 μM). Analysis of the activity against intracellular forms of the Tulahuen strain showed that this bis-AIA (EC50= 0.04 μM) was about 100-fold more active than Bz (2 μM). The trypanocidal effect was dissociated from the ability to trigger intracellular lipid bodies within host cells, detected by oil red labeling. Both an active compound (35DAP073) and an inactive compound (26SMB060) displayed similar activation profiles. Due to their high selectivity indexes, two AIAs (35DAP073 and 35DAP081) were moved toin vivostudies, but because of the results of acute toxicity assays, 35DAP081 was excluded from the subsequent tests. The findings obtained with 35DAP073 treatment of infections caused by the Y strain revealed that 2 days of therapy induced a dose-dependent action, leading to 96 to 46% reductions in the level of parasitemia. However, the administration of 10 daily doses in animals infected with the Colombiana strain resulted in toxicity, preventing longer periods of treatment. The activity of the combination of 0.5 mg/kg of body weight/day 35DAP073 with 100 mg/kg/day Bz for 10 consecutive days was then assayed. Treatment with the combination resulted in the suppression of parasitemia, the elimination of neurological toxic effects, and survival of 100% of the animals. Quantitative PCR showed a considerable reduction in the parasite load (60%) compared to that achieved with Bz or the amidine alone. Our results support further investigations of this class with the aim of developing novel alternatives for the treatment of Chagas disease.

UI MeSH Term Description Entries
D009593 Nitroimidazoles IMIDAZOLES having a nitro moiety. Nitroimidazole
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D000577 Amides Organic compounds containing the -CO-NH2 radical. Amides are derived from acids by replacement of -OH by -NH2 or from ammonia by the replacement of H by an acyl group. (From Grant & Hackh's Chemical Dictionary, 5th ed) Amide
D000578 Amidines Derivatives of oxoacids RnE(
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

F H Guedes-da-Silva, and D G J Batista, and M B Meuser, and K C Demarque, and T O Fulco, and J S Araújo, and P B Da Silva, and C F Da Silva, and D A Patrick, and S M Bakunova, and S A Bakunov, and R R Tidwell, and G M Oliveira, and C Britto, and O C Moreira, and M N C Soeiro
The efficacy of novel arylimidamides against Trypanosoma cruzi in vitro.
December 2011, Parasitology,
F H Guedes-da-Silva, and D G J Batista, and M B Meuser, and K C Demarque, and T O Fulco, and J S Araújo, and P B Da Silva, and C F Da Silva, and D A Patrick, and S M Bakunova, and S A Bakunov, and R R Tidwell, and G M Oliveira, and C Britto, and O C Moreira, and M N C Soeiro
In vitro trypanocidal activity of DB745B and other novel arylimidamides against Trypanosoma cruzi.
June 2011, The Journal of antimicrobial chemotherapy,
F H Guedes-da-Silva, and D G J Batista, and M B Meuser, and K C Demarque, and T O Fulco, and J S Araújo, and P B Da Silva, and C F Da Silva, and D A Patrick, and S M Bakunova, and S A Bakunov, and R R Tidwell, and G M Oliveira, and C Britto, and O C Moreira, and M N C Soeiro
Biological action of pyrazolopyrimidine derivatives against Trypanosoma cruzi. Studies in vitro and in vivo.
January 1987, Comparative biochemistry and physiology. C, Comparative pharmacology and toxicology,
F H Guedes-da-Silva, and D G J Batista, and M B Meuser, and K C Demarque, and T O Fulco, and J S Araújo, and P B Da Silva, and C F Da Silva, and D A Patrick, and S M Bakunova, and S A Bakunov, and R R Tidwell, and G M Oliveira, and C Britto, and O C Moreira, and M N C Soeiro
In vitro and in vivo effects of itraconazole against Trypanosoma cruzi.
March 1986, The American journal of tropical medicine and hygiene,
F H Guedes-da-Silva, and D G J Batista, and M B Meuser, and K C Demarque, and T O Fulco, and J S Araújo, and P B Da Silva, and C F Da Silva, and D A Patrick, and S M Bakunova, and S A Bakunov, and R R Tidwell, and G M Oliveira, and C Britto, and O C Moreira, and M N C Soeiro
In vitro and in vivo activity of certain thiosemicarbazones against Trypanosoma cruzi.
July 1974, Journal of medicinal chemistry,
F H Guedes-da-Silva, and D G J Batista, and M B Meuser, and K C Demarque, and T O Fulco, and J S Araújo, and P B Da Silva, and C F Da Silva, and D A Patrick, and S M Bakunova, and S A Bakunov, and R R Tidwell, and G M Oliveira, and C Britto, and O C Moreira, and M N C Soeiro
In vitro and in vivo activities of formycin B against Trypanosoma cruzi.
April 1985, Antimicrobial agents and chemotherapy,
F H Guedes-da-Silva, and D G J Batista, and M B Meuser, and K C Demarque, and T O Fulco, and J S Araújo, and P B Da Silva, and C F Da Silva, and D A Patrick, and S M Bakunova, and S A Bakunov, and R R Tidwell, and G M Oliveira, and C Britto, and O C Moreira, and M N C Soeiro
In vitro and in vivo activity of lignan lactones derivatives against Trypanosoma cruzi.
March 2007, Parasitology research,
F H Guedes-da-Silva, and D G J Batista, and M B Meuser, and K C Demarque, and T O Fulco, and J S Araújo, and P B Da Silva, and C F Da Silva, and D A Patrick, and S M Bakunova, and S A Bakunov, and R R Tidwell, and G M Oliveira, and C Britto, and O C Moreira, and M N C Soeiro
Antiproliferative effects and mechanism of action of SCH 56592 against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies.
July 1998, Antimicrobial agents and chemotherapy,
F H Guedes-da-Silva, and D G J Batista, and M B Meuser, and K C Demarque, and T O Fulco, and J S Araújo, and P B Da Silva, and C F Da Silva, and D A Patrick, and S M Bakunova, and S A Bakunov, and R R Tidwell, and G M Oliveira, and C Britto, and O C Moreira, and M N C Soeiro
In vitro and in vivo trypanocidal activity of a benzofuroxan derivative against Trypanosoma cruzi.
January 2021, Experimental parasitology,
F H Guedes-da-Silva, and D G J Batista, and M B Meuser, and K C Demarque, and T O Fulco, and J S Araújo, and P B Da Silva, and C F Da Silva, and D A Patrick, and S M Bakunova, and S A Bakunov, and R R Tidwell, and G M Oliveira, and C Britto, and O C Moreira, and M N C Soeiro
Activity of the sesquiterpene lactone goyazensolide against Trypanosoma cruzi in vitro and in vivo.
January 2020, Parasitology,
Copied contents to your clipboard!